300 related articles for article (PubMed ID: 35561299)
21. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
Navarro Matilla B; García-Marco JA
Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
[TBL] [Abstract][Full Text] [Related]
22. Treatment of older patients with mantle cell lymphoma in the era of novel agents.
Rozental A; Jim HSL; Extermann M
Leuk Lymphoma; 2023 Sep; 64(9):1514-1526. PubMed ID: 37357622
[TBL] [Abstract][Full Text] [Related]
23. [New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
Rousseau A; Thieblemont C
Bull Cancer; 2021 Feb; 108(2):142-144. PubMed ID: 33531153
[No Abstract] [Full Text] [Related]
24. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
[TBL] [Abstract][Full Text] [Related]
25. Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
McCulloch R
Br J Haematol; 2023 Aug; 202(4):718-719. PubMed ID: 37188352
[TBL] [Abstract][Full Text] [Related]
26. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
27. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
Klener P
Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
[TBL] [Abstract][Full Text] [Related]
28. CAR T-Cell therapy for the management of mantle cell lymphoma.
Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
[TBL] [Abstract][Full Text] [Related]
29. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
[TBL] [Abstract][Full Text] [Related]
30. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
Dreyling M; Ferrero S;
Haematologica; 2016 Feb; 101(2):104-14. PubMed ID: 26830211
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
Marchetti M; Visco C
Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538
[TBL] [Abstract][Full Text] [Related]
32. SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
Nayak RK; Gerber D; Zhang C; Cohen JB
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):861-865. PubMed ID: 37661513
[TBL] [Abstract][Full Text] [Related]
33. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bond DA; Alinari L; Maddocks K
Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
[TBL] [Abstract][Full Text] [Related]
34. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.
Arun Kumar S; Gao J; Patel SA
Leuk Res; 2023 Nov; 134():107385. PubMed ID: 37672954
[TBL] [Abstract][Full Text] [Related]
35. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
[TBL] [Abstract][Full Text] [Related]
36. Current regimens and novel agents for mantle cell lymphoma.
Chen Y; Wang M; Romaguera J
Br J Haematol; 2014 Oct; 167(1):3-18. PubMed ID: 24974852
[TBL] [Abstract][Full Text] [Related]
37. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
38. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L; Malpica L; Tummala S; Flowers C; Neelapu SS; Wang ML; Jain P
Leuk Lymphoma; 2024 May; 65(5):669-673. PubMed ID: 38248629
[No Abstract] [Full Text] [Related]
40. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.
Raghani NR; Shah DD; Shah TS; Chorawala MR; Patel RB
Crit Rev Oncol Hematol; 2023 Oct; 190():104085. PubMed ID: 37536448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
